Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 3/20 | 0.37 |
| ▸ | METAP2 | P50579 | 2/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24127726 | 1.00 | NPC1 (0.43) | NPC1HPGDSMN1; SMN2LMNACASP3 | |
| SCHEMBL24127717 | 0.88 | DYRK1A (0.37) | NPC1HPGDSMN1; SMN2LMNACASP3 | |
| SCHEMBL29720595 | 0.88 | DYRK1A (0.37) | NPC1HPGDSMN1; SMN2LMNACASP3 | |
| SCHEMBL29720500 | 0.84 | DYRK1A (0.35) | NPC1HPGDRAB9ADYRK1AKDM4E | |
| SCHEMBL24128024 | 0.84 | DYRK1A (0.35) | NPC1HPGDRAB9ADYRK1AKDM4E | |
| SCHEMBL24127737 | 0.76 | PDE10A (0.35) | HPGDSMN1; SMN2LMNANPSR1KDM4E | |
| SCHEMBL29720471 | 0.76 | TRPM8 (0.36) | SMN1; SMN2LMNAMETAP1METAP2NPSR1 | |
| SCHEMBL24127708 | 0.76 | TRPM8 (0.36) | SMN1; SMN2LMNAMETAP1METAP2NPSR1 | |
| SCHEMBL24128070 | 0.76 | KDM4E (0.34) | HPGDSMN1; SMN2LMNARAB9AMETAP1 | |
| SCHEMBL29720448 | 0.76 | PDE10A (0.35) | HPGDSMN1; SMN2LMNANPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC | 2023-07-20 | — | — | US | disclosed |
| EP-4168414-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | Shy Therapeutics LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| WO-2021257828-A9 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2022-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227466-A1 | SUBSTITUTED THIENOPYRIMIDINES THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | KRAS, G3BP1, NRAS | NPC1 4140/4885HPGD 1303/4885SMN1; SMN2 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.